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1561-5413/Copyright ª 2014, Hong KoSummary Background: Secondary hyperparathyroidism is common amongst dialysis patients
and is associated with increased morbidity and mortality. Vitamin D analogues are effective
treatments, but the adverse effects of traditional vitamin D preparations, especially hypercal-
cemia, are often dose-limiting.
Purpose: We studied the efficacy and safety of paricalcitol for the treatment of secondary hy-
perparathyroidism in hemodialysis patients.
Methods: We reviewed 13 adult hemodialysis patients treated with oral paricalcitol. The
dosage of paricalcitol was adjusted according to the clinical response.
Results: Serum parathyroid hormone (PTH) level decreased by 47.3  34.3% at 3 months and
74.7  36.8 % by 3 years. Eight patients (62%) responded and had reduction in PTH levels by
at least 30%; seven of them (87.5%) responded within the first 3 months. Responders had a
significantly lower baseline PTH level than the nonresponders (64.3  32.2 vs.
138.5  64.0 pmol/L, pZ 0.02). None of the patients developed hypercalcemia, but hyperpho-
sphatemia was present in all patients.
Conclusion: There is a substantial improvement in PTH levels by paricalcitol treatment in he-
modialysis patients with secondary hyperparathyroidism, and paricalcitol is generally well
tolerated. Our results suggest that patients with more advanced secondary hyperparathyroid-
ism tend to have a less favorable response.
背景：在血液透析患者間，次發性甲狀旁腺功能亢進是常見的疾病，會明顯增加患者的死亡與患
病率。維生素 D 類似物通常是有效的療法，但傳統製劑的臨床應用常受限於不良作用如高鈣血症
的出現。本研究以患有次發性甲狀旁腺功能亢進的血液透析患者為對象，調查了 paricalcitol 在
這方面的功效與安全性。
方法：本研究回顧了 13 位成年血液透析患者，正在接受口服 paricalcitol 治療，其劑量根據臨床
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8 V.W.-K. Kwong et al.結果：經過 3 個月及 3 年後，血清副甲狀腺素 (PTH) 水平分別下降 47.3  34.3% 及
74.7  36.8%。其中，8 人 (62%) 反應良好，PTH 降幅達至少 30%；他們之中有 7 人 (87.5%) 在
首 3 個月呈現反應。相比於不反應者，反應者的基線 PTH 明顯較低 (64.3  32.2 vs
138.5  64.0 pmol/L，p Z 0.02)。治療期間，無任何人出現高鈣血症，但所有病人均有高磷酸
血症的現象。
結論：對於患有次發性甲狀旁腺功能亢進的血液透析患者，paricalcitol可有效降低 PTH，且耐受
性良好。本研究的結果亦顯示，較晚期的次發性甲狀旁腺功能亢進患者，其療效反應可能較為不
明顯。Introduction
Secondary hyperparathyroidism is a common complication
in patients with chronic kidney disease (CKD), and is
characterized by markedly increased serum parathyroid
hormone (PTH) levels, phosphate retention, decrease in
serum calcium and 1,25-dihydroxycholecalciferol levels.1
As renal function declines, the initial increase in PTH is
appropriate for the correction of hypocalcemia and
hyperphosphatemia. However, excessive and autonomous
PTH secretion may lead to hypercalcemia and hyper-
phosphatemia due to the unchecked release of calcium
phosphate from bones. Patients with severe secondary
hyperparathyroidism are have a high risk of bone frac-
tures. Secondary hyperparathyroidism is also associated
with soft tissue and vascular calcification, which may lead
to an increase in cardiovascular morbidity and
mortality.2e6
The mainstay treatment options of secondary hyper-
parathyroidism include dietary phosphate restriction, oral
phosphate binders, vitamin D analogues, and calcimimetic
drugs.7 Notably, the use of the vitamin D analogues has
been found to be associated with a survival benefit in CKD
patients on hemodialysis.8,9 However, high dose treatment
of biologically active vitamin D (for example, 1,25-
dihydroxycholecalciferol) carries a high risk of hypercal-
cemia and hyperphosphatemia secondary to increased in-
testinal calcium absorption. More recently, the synthetic
vitamin D analogue paricalcitol (Zemplar, Abbott Labora-
tories, Hong Kong SAR, China) was approved for the treat-
ment of secondary hyperparathyroidism in CKD patients.
Studies showed that compared with naturally occurring
vitamin D, intravenous paricalcitol is a more effective
suppressor of PTH, with lower incidences of hypercalcemia
and hyperphosphatemia.10e13 In this retrospective study,
we aim to determine the efficacy and safety of oral par-
icalcitol in chronic hemodialysis patients with severe sec-
ondary hyperparathyroidism.Patients and methods
We reviewed 13 adult chronic hemodialysis patients in our
dialysis unit. All patients had severe secondary hyperpara-
thyroidism and were started on oral paricalcitol from 2008
to 2010. Patients who were on other synthetic vitamin D
analogues were discontinued before the study. None of the
patients had been treated with calcimimetics. Their clinical
records were reviewed. All patients were followed until
April 2013.Treatment protocol
Patients who were on regular alfacalcidol or calcitriol had
their vitamin D treatment stopped before switching to par-
icalcitol. The initial dosage was 2e4 mg, twice to thrice
weekly, as determined by their in-charge nephrologists.
Compliance to paricalcitol treatment was ensured by directly
observed therapy after the hemodialysis session under the
supervision ofa dialysis nurse. Serumcalcium,phosphate, and
alkaline phosphatase (ALP) levels were monitored at least
monthly. The serum PTH level was monitored every 3e6
months. The dosages of paricalcitol and oral phosphate
binders were adjusted according to the serum biochemistry.
Treatment response is defined as having a reduction in
serum PTH level by at least 30% from the average PTH level
in two consecutive measurements before paricalcitol
treatment. We also analyzed the proportion of patients
achieving a PTH level of below 33 pmol/L, the target level
as suggested in the Kidney Disease Outcomes Quality
Initiative (KDOQI) guidelines.14
Statistical analysis
Statistical analysis was performed by SPSS for Windows
software version 17.0 (SPSS Inc., Chicago, IL, USA). Data
were expressed as mean  SD if normally distributed, or
median (range) otherwise. Groups were compared using the
Student t test or the Chi-square test as appropriate. A p
value of less than 0.05 was considered significant. All
probabilities were two-tailed.
Results
The baseline characteristics of the study patients are
summarized in Table 1. Before paricalcitol treatment, 12
patients (92.3%) had a PTH level above 33 pmol/L. The
mean starting dose of paricalcitol was 9.0  2.8 mg/week;
the average dosage during follow up was 10.2  2.5 mg/
week. The mean duration of paricalcitol treatment was
43.5  18.6 months.
Treatment response
Fig. 1 showed the change in serum PTH levels during the
study period. Three months after paricalcitol therapy, the
mean serum PTH level decreased from 64.3  32.2 pmol/L
to 33.9  38.6 pmol/L (Wilcoxon rank sum test, pZ 0.036),
and then further decreased to 16.3  6.3 pmol/L (Wilcoxon
rank sum test, p Z 0.29) 3 years later, corresponding to a
Table 2 Comparison between responders and
nonresponders.
Responder Nonresponder p
No. of patients 8 5 d
Age (y) 64.4  7.5 54.8  9.7 0.07
Sex (M:F) 5:3 3:2 1.00
Duration of dialysis
(mo)
164.9  52.5 111.8  38.1 0.08
Kt/V 1.5  0.3 1.3  0.3 0.30
Baseline biochemistry
Serum PTH (pmol/L) 64.3  32.2 138.5  64.0 0.02*
Serum ALP (IU/L) 94.6  43.6 143.8  51.8 0.10
Serum calcium
(mmol/L)a
2.28  0.20 2.40  0.12 0.24
Serum phosphate
(mmol/L)
2.14  0.47 2.74  0.20 0.01*
Paricalcitol dose
(mg/wk)
9.50  2.78 8.20  2.86 0.43
ALP Z alkaline phosphatase; PTH Z parathyroid hormone.
a Adjusted by serum albumin level.
Table 1 Baseline demographics and clinical data.
No. of patients 13
Sex (M:F) 8:5
Age (y) 60.7  9.4
Duration of dialysis (mo) 144.5  53.0
Hours of HD per week (mean  SD) 12.4  1.8
Kt/V (per dialysis session) 1.4  0.3
Underlying renal diagnosis,
no. of patients (%)
Glomerulonephritis 4 (30.8)
Hypertensive nephropathy 3 (23.1)
Diabetic nephropathy 1 (7.7)
Polycystic kidney 1 (7.7)
Unknown 4 (30.8)
Major comorbidity, no. of patients (%)
Cardiovascular disease 3 (23.1)
Cerebrovascular disease 1 (7.7)
Baseline serum biochemistry
Calcium (mmol/l) 2.32  0.18
Phosphate (mmol/l) 2.37  0.49
Alkaline phosphatase (IU/L) 113  51
Parathyroid hormone (pmol/L) 92.8  58.2
Drug treatment
Vitamin D a (mg/d) 0.24  0.22
Calcium carbonate (mg/d) 3041.7  2150.1
Aluminum hydroxide (mg/d) 1628.6  667.6
a Alfacalcidol or calcitriol.
Paricalcitol for HD 9drop of serum PTH level of 47.3  34.3% by 3 months and
74.7  36.8 % by 3 years. The proportion of patients having
a PTH remained above 33 pmol/L drops to 62% by 3 months.
After starting on paricalcitol treatment, eight patients
(61.5%) responded, of which seven patients achieved the
target PTH level in the first 3 months. One patient had a
delayed response at 12 months after treatment.
The baseline characteristics of the responders and non-
responders are summarized and compared in Table 2. The
responders had a significantly lower baseline PTH level than
the nonresponders (64.3  32.2 vs. 138.5  64.0 pmol/L,
pZ 0.02) as well as a lower baseline serum phosphate level
(2.14  0.47 vs. 2.74  0.20 mmol/L, p Z 0.01). However,
no significant differences were found between the0
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Figure 1 Serum parathyroid hormone (PTH) levels during the
study period.responders and nonresponders in other baseline clinical or
biochemical parameters.
Adverse effects
A total of four patients had undergone parathyroidectomy
after unsuccessful medical treatment. Amongst those who
underwent parathyroidectomy, two were responders (25%)
and two were nonresponders (60%) and their difference was
not statistically significant (p Z 0.57). Parathyroidectomy
was performed in the two responders at 3 years and 6 years
before the start of paricalcitol. However, progression of their
PTH continued after their surgery, necessitating the use of
paricalcitol. The serum biochemistry before and 12 months
after paricalcitol treatment is summarized in Table 3. None of
the patients had hypercalcemia during paricalcitol treat-
ment. Both responders and nonresponders had normal
adjusted calcium levels throughout the study period. How-
ever, both groups had a mean phosphate level higher than
1.8 mmol/L, either before or after paricalcitol treatment.
Serum ALP levels did not have significant changes after par-
icalcitol treatment. Neither bone mineral density nor bone
biopsy was performed for detailed evaluation in any of the
patients. During the study, four patients died; three were
responders and one was a nonresponder. The causes of death
were sudden cardiac arrest (2 cases),myocardial infarction (1
case), and septicemia (1 case). One responder had fracture of
the superior pubic rami after a minor trauma 3 years after
paricalcitol treatmentwas started; the fracturewasmanaged
conservatively. Because the sample sizewas small, we did not
analyze the difference between the responders and non-
responders with regard to the incidence of cardiovascular
diseases and overall mortality.
Discussion
In this study, we examined the efficacy of oral paricalcitol
for the treatment of secondary hyperparathyroidism in
Table 3 Serum biochemistry before and 12 months after paricalcitol treatment.
Responder (n Z 8) p Nonresponder (n Z 5) p
0 mo 12 mo 0 mo 12 mo
Serum PTH (pmol/L) 64.3  32.2 33.5  27.2 0.024* 138.5  64.1 207.7  122.8 0.10
Serum calcium (mmol/L)a 2.28  0.20 2.40  0.14 0.42 2.40  0.12 2.47  0.10 0.14
Serum phosphate (mmol/L) 2.14  0.47 2.34  0.48 0.56 2.74  0.20 2.65  0.41 0.71
Serum ALP (IU/L) 94.6  43.6 114.6  56.8 0.49 143.8  51.8 166.2  132.0 0.65
a Adjusted by serum albumin level.
10 V.W.-K. Kwong et al.long-term hemodialysis patients. We chose to start with low
dose pulsed paricalcitol therapy initially and titrate up if
necessary in following visits, as opposed to starting at a
higher dose then a titrate-down strategy. This approach has
been shown by Mitsopoulos et al15 to have the benefit of
avoiding the risk of a more rapid increase in the serum
calcium level, as well as avoiding the initial over-
suppression of PTH. In that study, there was no significant
delay in the time needed to achieve the targeted PTH
reduction.15 Therefore, the start-low, then titrate-up
method may be the most desirable approach.
Although most of our patients received alfacalcidol or
calcitriol therapy before the study, only a minority of them
had PTH levels that achieved the target value. Previous
studies have shown that paricalcitol effects in a faster PTH
suppression than traditional vitamin D analogues.13,16 Llach
et al10 actually showed that paricalcitol could successfully
control secondary hyperparathyroidism in patients resistant
to calcitriol therapy. After paricalcitol therapy, the propor-
tion of patients achieving the PTH target continued to in-
crease throughout the first 12 months. Notably,
nonresponders actually had an increase in their PTH levels
after treatment, probably due to the progression of the un-
derlying disease. Our observation is in line with the findings
from other studies on paricalcitol treatment.10,16,17 The
mean PTH reduction achieved ranging from 27.8% by 3
months of treatment in Ross’s study,14 to 42.39% at 6 months
in Ramos’ study,17 and by 82% by 16months in Llach’s study.10
Similarly, in our study, PTH levels dropped from the baseline
by 47.3% at 3 months and 74.7% at 42 months.
In our present study, serum calcium, phosphate, and ALP
levels had no significant changes before and after par-
icalcitol treatment. In contrast, some previous studies
found that serum calcium, phosphate, and ALP levels, as
well as the calcium-phosphate product, are lower with
paricalcitol than calcitriol treatment.11e13 In fact, we
found that the phosphate levels of our patients remained
above target after treatment. This result was also shown in
the multi-center study reported by Sprague et al.13
There had been little research on the patient charac-
teristics that are associated with a favorable response in
paricalcitol treatment. In our present study, there was no
relationship between treatment responsiveness and age,
gender, duration and adequacy of dialysis, baseline serum
calcium, ALP levels, or the history of prior vitamin D
treatment. However, we found that responders had a
significantly lower baseline PTH and phosphate level than
nonresponders. We believe a grossly elevated PTH level
may represent advanced parathyroid gland hyperplasia and
possibly autonomous PTH secretion, explaining the poorresponsiveness to paricalcitol treatment in this group of
patients. Similarly, Vulpio et al18 also showed that the size
of parathyroid gland is related to the responsiveness to
paricalcitol treatment. In that study, serum calcium and
phosphate concentrations also increased in those with
substantially enlarged parathyroid glands.18 Unfortunately,
we have no information on the size of parathyroid gland in
our study patients.
It should be noted that most of the previous study on
paricalcitol used intravenous treatment, and compliance
can be ensured as most centers schedule the injections to
match the hemodialysis sessions. By contrast, oral treat-
ment may appear less efficacious because drug compliance
may be compromised. In our study, compliance is ensured
by directly observed therapy during the dialysis session. It is
interesting to note that in a previous study, Mittman et al11
found that there is a significant decrease in all-cause
missed doses in patients treated with oral paricalcitol
than those with calcitriol.
There are some shortcomings of our study. First, our
sample size is small and we do not have adequate statistical
power to detect less common adverse effects of paricalcitol
treatment. Moreover, we do not have a control group and
most of our patients received vitamin D therapy (either
alfacalcidol or calcitriol) prior to the study. As a result, our
findings may be biased. Similarly, we do not have detailed
imaging study on the parathyroid gland for our patients.
The long-term effect of paricalcitol treatment on para-
thyroid gland size is an interesting topic for further study.
In conclusion, we observed a substantial improvement in
the PTH levels by paricalcitol treatment in hemodialysis pa-
tients with secondary hyperparathyroidism, and paricalcitol
treatment is generally well tolerated. Our results suggest
that patients with more advanced secondary hyperparathy-
roidism (e.g., those with higher baseline PTH levels) tend to
have a less favorable response to paricalcitol treatment.Conflicts of interest
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